CCN2 and chronic kidney disease: To treat kidney fibrosis in chronic kidney disease, a novel CTGF–CT domain-specific peptide, named 810A, was developed to block the interaction between CTGF and its epidermal growth factor receptor, thereby inhibiting the STAT3 phosphorylation and cellular ECM protein synthesis to alleviate the process of kidney fibrosis [126].